000 | 03536nam a2200421 a 4500 | ||
---|---|---|---|
003 | MX-TeUDD | ||
005 | 20240306161816.0 | ||
008 | 031016b2005 njuad gr 001 0 eng c | ||
020 | _a1588292002 | ||
020 | _a9781588292001 | ||
040 |
_aMX-TeUDD _bspa _cMX-TeUDD |
||
041 | _aeng | ||
050 | 0 | 4 |
_aRC271.C5 _bO4 2005 |
245 | 0 | 0 |
_aCombination cancer therapy : _bmodulators and potentiators / _cedición, Gary K. Schwartz. |
246 | 2 | _aModulators and potentiators. | |
260 |
_aTotowa, N.J. : _bHumana, _c2005 |
||
300 |
_a284 p. : _bil., gráf. ; _c23 cm. |
||
490 | 0 | _aCancer drug discovery and development | |
504 | _aIncluye referencias bibliográficas. | ||
505 | 2 | _a1. Targeting of the EGFR as a modulator of cancer chemotherapy.-- 2. Cyclin-dependent kinase inhibitors in combination chemotherapy.-- 3. Development of protein kinase C and cyclin-dependent kinase inhibitors as potentiators of cytotoxic drug action in leukemia.-- 4. Carboxyamidotriazole, an inhibitor of nonvoltage-operated calcium entry: single-agent and combination therapy for ovarian carcinoma.-- 5. Targeted F-particle therapy: a rational approach to drug development in hematologic diseases and solid tumors.-- 6. Pharmacological modulation of fluoropyrimidines: building on the lessons of the past.-- 7. Development of inhibitors of HER2 with taxanes: new directions in breast cancer therapy.-- 8 Targeting NF-PB to increase the activity of cisplatin in solid tumors.-- 9. Combinations of chemotherapy and G3139, an antisense Bcl-2 oligonucleotide.-- 10. Use of animal models to evaluate signal transduction inhibitors as modulators of cytotoxic therapy. | |
520 | 2 | _aExpert physician-scientists and clinicians review those combinations of novel target agents classic chemotherapies that hold the most promise for the future of medical oncology, and detail their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory bench top to the patient's bedside for the future treatments in cancer therapy. | |
526 | 8 | _aSalud | |
650 | 0 |
_aDrug interactions. _949258 |
|
650 | 4 |
_aApoptosis. _949259 |
|
650 | 0 |
_aCancer _xChemotherapy. _981766 |
|
650 | 4 |
_aCáncer _xQuimioterapia. _910182 |
|
650 | 4 |
_aCáncer _xTratamiento. _981184 |
|
650 | 4 |
_aOncología. _972284 |
|
650 | 4 |
_aMedicina. _921519 |
|
700 | 1 |
_aSchwartz, Gary K., _eed. _949263 |
|
856 |
_uhttps://web.archive.org/web/20240306235941/https://media.springernature.com/full/springer-static/cover-hires/book/978-1-59259-864-9?as=webp _zPortada. (Wayback Machine, Internet Archive). |
||
856 |
_uhttps://books.google.bj/books?id=4K0si9SvzRIC&printsec=frontcover&hl=es _zGoogle Book. |
||
856 |
_uhttps://web.archive.org/web/20240306235935/https://link.springer.com/book/10.1385/1592598641#toc _zMás información. (Springer. / Wayback Machine, Internet Archive). |
||
856 |
_uhttps://web.archive.org/web/20240307001045/https://link.springer.com/content/pdf/bfm:978-1-59259-864-9/1?pdf _zTabla de contenido. (Wayback Machine, Internet Archive). |
||
905 | _aAcervo | ||
906 |
_aRocio _b20050823 |
||
942 |
_cBK01 _2lcc |
||
999 |
_c269387 _d269387 |
||
907 |
_c1 _dAlejandro Alberto Castrejón Murillo |